top of page


August 15, 2023

SiVEC's CEO, Lyndsey Linke, was recently featured on the Integrate & Ignite Marketing Podcast

Host Lori Jones and Lyndsey dive into her journey of co-founding SiVEC, a game-changing biotech company with a groundbreaking drug delivery platform, and how the team is making waves in the industry as a top emerging company. The interview also talks about the incredible ecosystem supporting technology development in Colorado! Join us for this exciting conversation about commercializing science, acquiring business acumen, and embracing a risk-taking mindset. 

May 23, 2023

SiVEC’s CEO and co-founder, Dr. Lyndsey Linke, has been appointed as a new board member for the Colorado BioScience Association

As a visionary health innovator who is passionate about building and growing successful life sciences companies in Colorado, Lyndsey is honored to be recognized as a respected leader in the life science’s community. She looks forward to beginning this new endeavor where she will work closely with CBSA, CBSA members, and Colorado’s life science community as they continue to gain momentum and advance Colorado’s life science ecosystem to the top 5!

May 18, 2023

SiVEC Biotechnologies awarded grant from the Colorado Office of Economic Development and International Trade

Our exceptional team at SiVEC Biotechnologies has reached yet another milestone! The grant awarded by the Colorado Office of Economic Development and International Trade is a testament to SiVEC’s hard work and dedication to their mission of advancing nucleic acid and gene therapies with a focus on safe and precise tissue-targeted delivery. This $250,000 grant will enable SiVEC to advance a first-in-class cancer therapeutic targeting oncogenic-KRAS into IND-enabling stages.

April 27, 2023

SiVEC Biotechnologies wins first prize in the Innovator's Pitch Challenge Digital RESI March

The Innovator’s Pitch Challenge allows early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of active investors and industry experts. 

The March event, a perennial highlight of RESI, featured more than 34 competing companies. Among the presenters, Dr. Lyndsey Linke (SiVEC CEO) was awarded the first place prize.

February 5, 2023

SiVEC Biotechnologies publishes paper on the safety and efficacy of its live bacterial delivery vehicle

The new publication, published on February 5, 2023, appears in the journal Engineering in Life Sciences.

SiVEC is pleased to announce the publication of our groundbreaking scientific paper entitled "An optimized live bacterial delivery vehicle safely and efficaciously delivers bacterially transcribed therapeutic nucleic acids" in the journal Engineering in Life Sciences on February 5, 2023. The paper describes a new delivery platform that addresses the limitations of current nucleic acid delivery systems, including poor targeting specificity, inefficient access to target cell cytoplasm, immune activation, off-target effects, small therapeutic windows, limited genetic encoding and cargo capacity, and manufacturing challenges. The new platform comprises engineered live, tissue-targeting, non-pathogenic bacteria that specifically bind to epithelial cells via a surface-expressed targeting ligand, allow escape of their cargo from the phagosome, and have minimal immunogenicity. The paper reports the platform's ability to deliver short hairpin RNA (shRNA) to various tissues and describes its minimal immunogenicity. The authors validated the platform's therapeutic potential by using it to deliver influenza-targeting antiviral shRNAs to respiratory tissues in vivo, establishing its safety and efficacy for use in multiple tissue types and as an antiviral in the mammalian respiratory tract. This optimized delivery platform is expected to enable a variety of advanced therapeutic approaches.

September 14, 2022

SiVEC Biotechnologies recognized as the 2022 Top Emerging Start-Up Company by BIO International

SiVEC's CEO Lyndsey Linke participated in the BIO International Start-Up Stadium, a competition featuring live pitches from 42 finalist companies.

“This year’s BIO Start-Up Stadium had record-setting participation from the number of start-up applicants, number of start-up’s pitching, number of judges, and sizes of audiences attending since the program launched in 2015,” said Bernard V. Fallon, BIO’s Managing Director of Industry Research, Investor Outreach, and Education.

SiVEC Biotechnologies scored the highest among the emerging start-up companies, in a competition featuring live pitches from 42 finalist competitors.

September 23, 2021

SiVEC Biotechnologies receives funding from NIH/NCATS to develop its delivery platform for gene editing machinery


This funding represents SiVEC's second phase I SBIR award, highlighting the value appreciated by the NIH and expert review panels.


The therapeutic potential of gene editing is limited by several shortcomings of current delivery platforms (e.g., viruses, mechanical, and non-viral), including weak targeting to specific cells or tissues, limited cargo size, difficulties in cellular entry, immune activation, off-target events, and manufacturing challenges. In this project, SiVEC will engineer its core delivery platform, which consists of invasive, tissue-targetable, non-immunogenic bacteria, for in vivo delivery of CRISPR/Cas gene editing components. Successful leveraging of SiVEC’s previously validated delivery platform will overcome these key limitations, thereby providing a new tool in the quest to realize the full potential of gene editing in the treatment of human disease.

September 23, 2021

SiVEC Biotechnologies selected to participate in the 2021 NIH Innovation Conference and Life Science Summit

SiVEC has been selected as an emerging biotech company to participate in the 2021 NIH Innovation Conference (Monday, October 4th), and Life Science Summit (LSS - a two-day virtual event Tuesday, November 9th and Wednesday, November 10th). The two-day LSS program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It will also feature informative plenary sessions, business workshops, and therapeutic sessions. The opportunity to present at these two prestigious events is a great recognition and tribute to the innovative work behind SiVEC.

September 23, 2021

Osage University Partners features CEO Lyndsey Linke as an inspiring female founder

As part of their celebration of National Women's Small Business Month this October, the VC firm OUP interviewed Lyndsey to discuss her journey as a female founder. Their goal was "to showcase real-life examples of women in academia and industry with the hope that hearing these journeys from bench to entrepreneur will provide inspiration and guidance to more potential entrepreneurs". Visit the link below to read her interview.

March 23, 2021

SiVEC Biotechnologies wins pitch competition at Amgen-CBSA Healthcare innovation event

SiVEC CEO Dr. Lyndsey Linke competed in and won the pitch competition at the Amgen-CBSA Healthcare Innovation event held March 23, 2021. SiVEC received a grant from Amgen as well as mentoring from Amgen experts. This event, sponsored by Amgen in partnership with Colorado BioScience Association, was held to bring together various members of Colorado's life sciences and healthcare ecosystem.

May 21, 2020

SiVEC Biotechnologies Awarded Colorado Advanced Industry Funding

SiVEC Biotechnologies has been awarded a $250,000 grant under the Colorado Office of Economic Development and International Trade (OEDIT)’s Advanced Industries Accelerator Grant Program. This Early Stage Capital and Retention grant is intended to fund companies like SiVEC who are commercializing innovative technologies to create viable products that meet a market need and can be created or manufactured in Colorado and exported globally.

May 11, 2020

Phase II NIH NIAID Funding Awarded to SiVEC for Human Influenza Antiviral Development

Following successful completion of a Phase I SBIR funded by the NIH, SiVEC Biotechnologies has been awarded a Phase II grant for continued development of SiVEC-IAV antiviral for human influenza treatment and prevention, built on SiVEC's novel bacterial delivery platform. Phase II funding from NIH NIAID provides $3 million over three years to support IND-directed work including preclinical and preliminary CMC activities. 

November 05, 2018

First Place in InnoSTARS Competition Biotechnology & Healthcare Industry Final Awarded to SiVEC Biotechnologies

SiVEC Biotechnologies was awarded first place in the InnoSTARS Competition Biotechnology & Healthcare Industry final, hosted in Suzhou, China. Of the over 900 U.S.-based start-up companies that applied to participate in the InnoSTARS Competition, SiVEC was one of fourteen companies in the Healthcare & Biotechnology sector that advanced from the preliminary rounds to compete in China. We are honored to receive this recognition of the significant market opportunity for SiVEC Biotechnologies in China, the world's largest poultry producing country. 

August 21, 2018

NIH Phase I SBIR Grant Awarded to SiVEC Biotechnologies

SiVEC Biotechnologies has officially been awarded a Phase I Small Business Innovation Research (SBIR) grant funded by the National Institutes of Health (NIH). This one-year grant provides funding to support research towards the enhancement of SiVEC's nucleic acid delivery platform for a variety of infectious diseases with applications in humans and other animals. The proposed scope of work includes both in vitro and in vivo work, culminating is a study using a mammalian disease model. A Research Associate/Postdoctoral Research Associate will be hired to assist with this work; please check the Careers page for more information in September 2018!  

April 27, 2018

SiVEC Biotechnolgies Advances to InnoSTARS Competition Semi-Finals in China

The 2018 InnoSTARS Competition is a platform that connects U.S.-based innovators and companies with Chinese investors, corporations, and strategic partners. InnoSTARS is the one and only innovation competition officially supported by the governments of United States of America and of People’s Republic of China. Winning U.S. companies will be able to showcase their business in targeted cities and have one-on-one matchmaking meetings with leading Chinese investors, partners, and industry executives that are hand-picked to fit company needs and purposes.


SiVEC Biotechnologies was a finalist in the preliminary pitch competition in Denver and now has the opportunity to travel to China for the semi-finals and networking in early-November 2018.

August 17, 2016

Colorado startup’s work helps prevent spread of disease

Lyndsey Linke is a master in the field of biotechnologies. 

Hear her story about developing a startup company that tackles serious problems while making a profit in the video clip above.

July 07, 2016

The day after Lyndsey Linke won the 2016 Colorado State University’s Collegiate Challenge business pitch competition, she boarded a plane for North Carolina to compete in the U.S. Masters Swimming national championship. Her competitive spirit and drive have been fueled over the years through swimming. She now brings that same intensity to the table as the founder of SiVEC Biotechnologies.

Linke has developed a technology that inhibits the flu virus from replicating, and can be used before flocks are infected. Her novel idea? An aerosol delivery system that allows the antiviral to be applied quickly, on a broad scale. It offers 90 percent protection and is inexpensive. All those things add up to SiVEC having an impact. “From the very beginning, the idea wasn’t just that I would develop something. This has the potential to change the industry, not just in the United States but globally,” Linke said.

May 26, 2016

SiVEC Biotech takes $20K top prize at CSU Collegiate Challenge competition

SiVEC Biotechnologies won the $20,000 top prize at the  Colorado State University Collegiate Challenge  pitch competition on Wednesday. The company, a CSU research spinoff headed by former student Lyndsey Linke, is developing antiviral products for the commercial poultry industry.

May 26, 2016

SiVec Biotechnologies wins CSU Collegiate Challenge, $20,000 for business

April 28, 2016 - Fourteen Collegiate business startups began the day on April 27 at the Colorado State University Lory Student Center for the CSU Collegiate Challenge in hopes of winning $20,000 to support their business.

This is the third year of the CSU Collegiate Challenge and it is designed to showcase the business startup community in northern Colorado as well as to celebrate entrepreneurship. Past and present students of universities from Colorado, Utah, Arizona, Kansas and Nebraska all come together to pitch startup business ideas.

May 26, 2016

SiVEC Biotechnologies wins top prize at CSU Collegiate Challenge

April 28, 2016 - SiVEC Biotechnologies, a startup founded by Colorado State University graduate student Lyndsey Linke, took home the $20,000 top prize from the CSU Collegiate Challenge business pitch competition on Wednesday night...

Please reload

bottom of page